Today: 11 April 2026
Subscribe
Browse Category

Pharmaceuticals 30 January 2026 - 1 February 2026

Johnson & Johnson stock price: JNJ in focus after EU panel backs Akeega expansion

Johnson & Johnson stock price: JNJ in focus after EU panel backs Akeega expansion

Johnson & Johnson shares closed Friday nearly flat at $227.25 after EU advisers backed expanded use of its prostate cancer drug Akeega. The Committee for Medicinal Products for Human Use recommended approval for patients with BRCA1/2 mutations. The final decision rests with the European Commission. Traders are watching Monday’s open and upcoming U.S. economic data.
1 February 2026
···
Amgen stock heads into earnings week after ending Kyowa Kirin eczema pact

Amgen stock heads into earnings week after ending Kyowa Kirin eczema pact

Amgen shares fell 0.3% to $341.88 Friday after disclosing plans to end its 2021 partnership with Kyowa Kirin, which will regain global rights to the eczema drug rocatinlimab. Amgen will report fourth-quarter and full-year earnings after markets close Feb. 3, with investors focused on pipeline priorities following the Kyowa Kirin exit.
31 January 2026
····
Novo Nordisk Class B stock price: Wegovy pill scripts hit 26,000 as earnings week approaches

Novo Nordisk Class B stock price: Wegovy pill scripts hit 26,000 as earnings week approaches

Novo Nordisk Class B shares closed down 0.23% at 369.55 Danish kroner Friday, capping a 7.9% slide over five sessions. U.S. prescriptions for oral Wegovy reached 26,109 in the week ending Jan. 23, after 3,071 in the first four days post-launch. The company faces rising competition in China and awaits EU approval for its MASH drug. Quarterly results and 2026 outlook are due Feb. 4.
31 January 2026
···
AstraZeneca share price: $18.5 billion China obesity-drug deal puts AZN stock in focus for Monday

AstraZeneca share price: $18.5 billion China obesity-drug deal puts AZN stock in focus for Monday

AstraZeneca agreed to license obesity drug candidates from CSPC Pharmaceutical in a deal worth up to $18.5 billion, paying $1.2 billion upfront. AstraZeneca shares rose 0.65% in London, while CSPC shares fell nearly 12% in Hong Kong. The deal gives AstraZeneca rights outside Greater China and includes a once-monthly GLP-1/GIP agonist entering Phase I trials. AstraZeneca will also delist its ADS from Nasdaq and move to the NYSE.
31 January 2026
··
Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Eli Lilly shares rose 1.3% after announcing a $3.5 billion Pennsylvania plant for obesity drugs, helping the Health Care Select Sector SPDR Fund gain 0.6% as the S&P 500 fell. Biotech lagged, with Corcept Therapeutics dropping 10.6% after an FDA rejection. Thermo Fisher slid 2.3% on weak profit guidance. Stryker jumped 4.3% after raising its outlook.
31 January 2026
······
AbbVie stock (ABBV) firms up into earnings week as markets turn cautious

AbbVie stock (ABBV) firms up into earnings week as markets turn cautious

AbbVie shares rose 1.17% to $223.01 Friday, outperforming a broader market dip after Donald Trump nominated Kevin Warsh to lead the Federal Reserve. Trading volume in AbbVie topped its 50-day average ahead of next week’s earnings report. The stock remains about 9% below its 52-week high. AbbVie will release results and hold its earnings call early Wednesday.
31 January 2026
···
Eli Lilly stock price (LLY): $3.5B plant, EU Mounjaro call and earnings ahead — what to watch

Eli Lilly stock price (LLY): $3.5B plant, EU Mounjaro call and earnings ahead — what to watch

Eli Lilly shares rose 1.3% to $1,037.15 after announcing a $3.5 billion injectable drug plant in Pennsylvania, set to create 850 permanent jobs by 2031. The plant will produce next-generation weight-loss drugs, including retatrutide. The European regulator declined a new use for Mounjaro in heart failure but will update prescribing info. Lilly’s Q4 results are due Feb. 4.
31 January 2026
···
Novavax stock drops 6% into the weekend as Pfizer Matrix‑M cash and earnings clock loom

Novavax stock drops 6% into the weekend as Pfizer Matrix‑M cash and earnings clock loom

Novavax shares fell 6.4% to $8.85 at Friday’s close, underperforming the broader market. Trading volume topped 5 million shares, above the 50-day average. Investors are watching for updates on partner-driven cash, including a $30 million upfront payment expected in Q1 2026 from a license deal. Novavax delayed its profitability target to 2028 and projects 2026 adjusted revenue of $185–$205 million.
31 January 2026
····
Eli Lilly stock climbs after $3.5 billion Pennsylvania plant plan as traders eye Feb. 4 results

Eli Lilly stock climbs after $3.5 billion Pennsylvania plant plan as traders eye Feb. 4 results

Eli Lilly shares rose 1.3% to $1,037.15 in after-hours trading Friday after announcing a $3.5 billion facility in Fogelsville, Pennsylvania to produce injectable weight-loss drugs, including retatrutide. Pennsylvania will contribute $100 million to the project, which is expected to create 850 permanent jobs and start operations by 2031.
31 January 2026
···
Merck stock rises as markets wobble — what to watch before the Feb. 3 earnings call

Merck stock rises as markets wobble — what to watch before the Feb. 3 earnings call

Merck shares rose 1.2% to $109.64 Friday afternoon, outperforming a falling S&P 500. Health care stocks attracted buyers as inflation data came in hotter than expected and Donald Trump named Kevin Warsh as Federal Reserve chair. Investors are watching for Merck’s Feb. 3 earnings call, with focus on 2026 guidance and Keytruda sales trends.
30 January 2026
···
AbbVie stock rises as ABBV heads into Feb. 4 earnings; Botox price talks in focus

AbbVie stock rises as ABBV heads into Feb. 4 earnings; Botox price talks in focus

AbbVie shares rose about 1% Friday, closing near $222.73 ahead of its Feb. 4 earnings report and first 2026 guidance. Investors are watching Botox pricing risks after Medicare listed it for price negotiations, and new aesthetics data from Paris. The stock dropped 2.35% Wednesday, ending a five-day rally. Goldman Sachs kept a neutral rating with a $223 target.
30 January 2026
···
Eli Lilly stock barely budges after $1.93bn autoimmune pact; Trump touts six U.S. plants

Eli Lilly stock barely budges after $1.93bn autoimmune pact; Trump touts six U.S. plants

Eli Lilly shares closed up 0.03% at $1,024.14 after announcing new research deals in autoimmune disease and gene-editing for hearing loss. Repertoire Immune Medicines will receive $85 million upfront in a collaboration potentially worth $1.84 billion. Lilly also signed a gene-editing agreement with Seamless Therapeutics valued up to $1.12 billion. Investors await Feb. 4 earnings for updates on demand and supply.
30 January 2026
···
1 … 6 7 8 9 10 … 38

Stock Market Today

  • Cocoa Prices Rise as Dollar Weakness Triggers Short Covering Amid Supply, Demand Concerns
    April 11, 2026, 3:25 AM EDT. Cocoa prices surged with May ICE NY cocoa up 2.66% and London cocoa gaining 2.37%, driven by short covering after dollar weakness. London fund shorts hit an 8-year high, adding fuel to the rally. Despite increased shipments from Ivory Coast and record ICE inventories signaling ample supply, drought in West Africa and fertilizer cost rises from Strait of Hormuz closure support prices. Demand remains weak; Easter chocolate sales estimate a 5% drop, with Barry Callebaut reporting a 22% sales volume decline. European cocoa grindings fell 8.3% year-on-year in Q4, exceeding expectations, reflecting ongoing consumption challenges amid high chocolate prices.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 11.04.2026

11 April 2026
LIVEMarkets rolling coverageStarted: April 11, 2026, 12:00 AM EDTUpdated: April 11, 2026, 3:35 AM EDT Cocoa Prices Rise as Dollar Weakness Triggers Short Covering Amid Supply, Demand Concerns April 11, 2026, 3:25 AM EDT. Cocoa prices surged with May ICE NY cocoa up 2.66% and London cocoa gaining 2.37%, driven by short covering after dollar weakness. London fund shorts hit an 8-year high, adding fuel to the rally. Despite increased shipments from Ivory Coast and record ICE inventories signaling ample supply, drought in West Africa and fertilizer cost rises from Strait of Hormuz closure support prices. Demand remains weak; Easter
UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

10 April 2026
London’s FTSE 100 rose 0.38% to 10,644.28 late Friday morning as investors awaited U.S.-Iran talks in Pakistan. Brent crude climbed 1% to $96.83 a barrel, while sterling eased but was on track for its biggest weekly gain since January. The FTSE 250 gained 0.79%. Britain’s 10-year gilt yield stood at 4.807%.
US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

10 April 2026
Dow e-minis slipped 0.15% before Friday’s open, with S&P 500 and Nasdaq 100 futures each down 0.08% as traders awaited March CPI data and watched U.S.-Iran tensions. Economists expect headline CPI to rise 0.9% for March and 3.3% year-on-year. Weekly jobless claims increased to 219,000. Brent crude traded near $97 a barrel, while shipping through the Strait of Hormuz remained well below normal.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 10.04.2026

10 April 2026
LIVEMarkets rolling coverageStarted: April 10, 2026, 12:00 AM EDTUpdated: April 10, 2026, 11:59 PM EDT Orora ASX:ORA Faces Earnings Reset After Saverglass Impact and Middle East Disruptions April 10, 2026, 11:59 PM EDT. Orora (ASX:ORA) shares plunged over 8% in one day following a guidance update that revealed an earnings reset at its Saverglass unit due to Middle East supply chain disruptions and a shutdown at the Ras Al Khaimah glass plant. Despite a sharp short-term loss, Orora's 90-day share price rise exceeds 33%, contrasting a longer-term 10.58% annual total shareholder return decline amid ongoing sector pressures. Trading at A$1.49,
Go toTop